AMT-676 in Patients With Advanced Solid Tumors
Recruiting now · Early Phase 1
Conditions studied: Advanced Solid Tumors
In brief
This is a first-in-human, open-label, multicenter Phase Ia/Ib study of AMT- 676, followed by an open-label, multicenter, dose-escalation.
Key facts
- Study ID
- NCT06400485
- Run by
- Multitude Therapeutics Inc.
- People needed
- 24
- Starts
- 2024-06-18
- Expected to finish
- 2027-12-31
- Last updated by the study team
- 2026-05-18
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- SCIENTIA Clinical Research Ltd — Randwick, New South Wales, Australia (enrolling)
- Macquarie University Hospital — Macquarie, New South wWales, Australia (enrolling)
- Gallipoli Medical Research Foundation — Greenslopes, Queensland, Australia (enrolling)
- Cabrini Hospital — Melbourne, Victoria, Australia (enrolling)
- Linear Research — Nedlands, Western Australia, Australia (enrolling)
- Shanghai East Hospital — Shanghai, Shanghai Municipality, China
- Sichuan Provincial People's Hospital — Chengdu, Sichuan, China
- Carolina Biooncology Institute — Huntersville, North Carolina, American Samoa
- Sir Run Run Shaw Hospital — Hangzhou, Zhejiang, China
- John Hopkins Sidney Kimmel Comprehensive Cancer Center — Philadelphia, Pennsylvania, American Samoa
- South Texas Accelerated Research Therapeutics (start) San Antonio — San Antonio, Texas, American Samoa
- Fujian Provincial Cancer Hospital — Fuzhou, Fujian, China
- Sun Yat-sen University Cancer Center — Guangzhou, Guangdong, China
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.